Disruption Isn’t Just About Volume — It’s About Proximity to Market
🧬 February 2026 | InnoDexis Disruption Heat Map Insights Oncology, Pharma & Biotech, and Fundamental Research collectively account for 57 high-disruption innovations in our latest dataset.
🚀 Disruption Isn’t Just About Volume — It’s About Proximity to Market
🧬 February 2026 | InnoDexis Disruption Heat Map Insights
Oncology, Pharma & Biotech, and Fundamental Research collectively account for 57 high-disruption innovations in our latest dataset.
Most of the scientists behind them don’t even know they’re being tracked.
Yet the real story isn’t just who publishes the most — it’s who is closest to changing markets.
🔬 What institutions rarely see about themselves:
Not their academic rank — but where they sit in the global disruption pipeline.
Here’s what this fortnight reveals:
📌 Applied Research Institutes — Empa | WSL-SLF | Fraunhofer
➡ Avg TRL 6.5+
➡ Built for translation
➡ Commercial orientation by design
📌 Research Universities — MIT | Northwestern University | EPFL
➡ High disruption density
➡ Avg TRL 3–4
➡ The global seeding ground
➡ 7 of MIT’s 8 innovations this fortnight carry high-disruption status — yet avg TRL is just 4.0
📌 Clinical Institutions — Mass General Brigham | Cedars-Sinai | Memorial Sloan Kettering Cancer Center
➡ Avg TRL 6.7
➡ Converting research into standard-of-care change
⚖️ The Strategic Insight:
Disruption volume ≠ disruption proximity.
MIT leads in output.
Empa leads in market-readiness.
Both matter — but at different decision horizons.
🎯 Universities seed the future.
🏭 Applied institutes industrialize it.
🏥 Clinical centers operationalize it.
The question is not who is best —
It’s where you sit on the disruption timeline.
🪞 InnoDexis gives institutions the mirror they’ve been missing — and the global context to understand how close their science is to reshaping markets.